Skip to main content
SpringerLink
Log in

Klinische Pharmakologie

  • Chapter
Beta-Interferon

  • 36 Accesses

Zusammenfassung

Die objektive Quantifizierung einer eingesetzten Interferonmenge ist nach wie vor eines der nicht zufriedenstellend gelösten Probleme bei der Bewertung dieser Wirkstoffe. Dies gilt aktuell auch fur Escoli-ß-Interferon. Die Hersteller von ß-Interferon haben, urn die Einheitlichkeit der Mengenangaben wenigstens annähernd sicherzustellen, neben einer ständig wiederholten Kalibrierung oder Eichung ihres Standardpräparates an dem offiziellen Standardpräparat der amerikanischen Gesundheitsbehörden (NIH) oder der Weltgesundheitsorganisation (WHO) ihr Produkt in regelmäßigen Zeiträumen in international anerkannten, unabhängigen Zentrallabors auf seinen Inhalt prüfen lassen. Darüber hinaushaben sie untereinander blinde, d. h. nicht mit der Mengenangabe des Inhalts ausgezeichnete Prüfpräparate, zur gegenseitigen Testung ausgetauscht. So konnte uber viele Jahre hinweg einigermalien sichergestellt werden, daß die Mengenangaben für Interferonpräparate international urn nicht wesentlich mehr als 15% schwankte. Seit dem ß-Interferon kommerziell eine größere Bedeutung zukommt, haben sich neu auf diesem Gebiet tätige Firmen, möglicherweise aus ungenügender Kenntnis der Sachiage und aus Geheimhaltungsgründen, nicht mehr an diese bewahrte Methode gehalten. Es ist deshalb heute recht schwierig geworden, Mengenangaben fur ß-Interferon auf ihre Richtigkeit hin einzuschätzen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Brzoska J, Obert H-J (1990) Immunmodulating effects of interferons: conclusions for therapy. In: Gross, Jablonska, Pfister, Stegner (eds) Genital papillomavirus infections. Springer, Berlin Heidelberg

    Google Scholar 

  • Brzoska J, Obert H-J (1987) Interferon gamma: Ein janusköpfiger Mediator bei Entzündungen. Arzneim-Forsch/Drug Res 37 (II), 12:1410–1416

    Google Scholar 

  • Caselmann WH, Eisenburg J, Hofschneider PH (1987) Interferon-beta und Interferon-gamma: eine schnelle und effektive Therapie der chronisch-aktiven Hepatitis B. In: Hofschneider PH (ed) Aktuelle Immunologic 3:37–41

    Google Scholar 

  • Dake H, Degre M (1976) Micro assay of mouse and human interferon. Acta Path Microbiol Scand Sect B 84:285–292

    Google Scholar 

  • Edwards BS, Merritt JA, Fuhlbridge RC (1985) Low doses of Interferon alpha result in more effective clinical natural killer cell activation. Clin Invest 75:1908–1913

    Article  CAS  Google Scholar 

  • Fierlbeck G, Schreiner T, Schaber B (1994) Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β. Cancer Immunol. Immunother. 39:263–268

    Article  PubMed  CAS  Google Scholar 

  • Fierlbeck G (1992) Pharmakokinetische Untersuchungen mit rekombinantem IFN-β im Vergleich zu natürlichem IFN-β. Habilitationsschrift der Eberhard-Karls-Universität zu Tübingen

    Google Scholar 

  • Goldstein D, Sielaff KM, Storer BE (1989) Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine. J Natl Cancer Inst 81:1061–1068

    Article  PubMed  CAS  Google Scholar 

  • Gross G, Ikenberg H, Roussaki A (1986) Systemic treatment of condylomata acuminata with recombinant Interferon α 2a: low dose superious to high dose regimen. Chemotherapie 32:537–541

    Article  CAS  Google Scholar 

  • Grups JW, Frohmüller HGW (1990) Influence of cyclic interferon-gamma on lymphocytes and their subpopulations in patients with renal carcinoma. Urology 35:111–113

    Article  PubMed  CAS  Google Scholar 

  • Hearl WG, Johnston MI (1987) Accumulation of 2′–5′-oligoadenylate in encephalomyocarditis virus-infected mice. J Virol 61:1686–1592

    Google Scholar 

  • Heidemann E, Dietz K, Obert H-J (1984) Günstigerer Verlauf des Herpes zoster bei immunsupprimierten Patienten unter Behandlung mit Fibroblasteninterferon. Onkologie 7:210–212

    Article  PubMed  CAS  Google Scholar 

  • Horisberger MA, Hochkeppel HK (1987) IFN-α induced human 78kD protein: Purification and homologies with the mouse Mx protein, production of monoclonal antibodies, and potentiation effect of IFN-γ. J Interferon Res 7:331–343

    Article  PubMed  CAS  Google Scholar 

  • IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis Neurology 43:655–661

    Google Scholar 

  • Jones A, Selby P (1991) Biological therapies. Radiotherapy Oncology 20:211–223

    Article  CAS  Google Scholar 

  • Klapper JA (1994) To the editor of Neurology. Neurology 44:186

    Google Scholar 

  • Kleinermann ES, Kurzrock R, Wyatt D (1986) Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res 46:5401–5405

    Google Scholar 

  • Knobler RL, Greenstein JI, Johnson KP (1993) Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up J. Interferon Res 13:333–340

    Article  PubMed  CAS  Google Scholar 

  • Koyama Y (1983) Pharmacokinetics and clinical trials of HuIFN-β in malignant tumors. In: Kishida T (ed) Interferons. ISIFN Kyoto, Japan

    Google Scholar 

  • Liberati AM, Garofani P, DeAngelis V (1994) Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J Interferon Res 14:61–69

    Article  PubMed  CAS  Google Scholar 

  • Liberati AM, Horisberger MA, Palmisano L (1992) Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. J Interferon Res 12:329–336

    Article  PubMed  CAS  Google Scholar 

  • Lodemann E, Nitsche EM, Lang MH (1985) Serum interferon level and (2′–5′) oligoadenylate synthetase activity in lymphocytes during clinical interferon application. J Interferon Res 5:621–628

    Article  PubMed  CAS  Google Scholar 

  • Mark DF, Lu SD, Creasey R (1984) Site-specific mutagenesis of the human fibroblast interferon gene. Proc Natl Acad Sci USA 81:5662–5666

    Article  PubMed  CAS  Google Scholar 

  • Obert H-J (1983) Praktische Aspekte der Interferontherapie. Inform Arzt 11:4–8

    Google Scholar 

  • Palmisano L, Salmon P, LeCotonnec JY (1990) Comparative pharmacokinetics and pharmacodynamics of beta interferon following 3 routes of administration. J Interferon Res 10:125

    Google Scholar 

  • Pestka S (1985) The human interferons: Structure, biological activity and receptors. In: Kirchner H, Schellekens H. (eds) The biology of the interferon system, Elsevier, Amsterdam, pp. 311

    Google Scholar 

  • Preble OT, Rothko K, Klippel JH (1983) Interferon induced 2′–5′ adenylate synthetase in vivo and interferon production in vitro by lyphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 157:2140–2146

    Article  PubMed  CAS  Google Scholar 

  • Preble OT, Yeh TJ, Silverman RH (1985) Interferon and 2′–5′ A synthetase in patients with immune diseases. Proc Clin Biol Res 202:415–422

    CAS  Google Scholar 

  • Read SE, Williams BRG, Coates RA (1985a) Elevated levels of interferon-induced 2′–5′-oligoadenylate synthetase in generalized persistent lymphadenopathy and the aquired immunodeficiency syndrome. J Infect Dis 152:466–472

    Article  PubMed  CAS  Google Scholar 

  • Read SE, LeBrocq FJ, Williams BRG (1985b) Persistant elevation of 2′–5′ A synthetase and prognosis in the aids-related complex (ARC). Prog Clin Res 202:405–413

    CAS  Google Scholar 

  • Royer HD, Reinherz EL (1987) T lymphocytes: Ontogeny, function, and relevance to clinical disorders. N Engl J Med 317:1136–1142

    Article  PubMed  CAS  Google Scholar 

  • Saito TJ (1986) 2′5′-01igoadenylate synthetase activity in serum of healthy subjects and of homosexual men infected with human immunodeficiency virus. Tokyo Women’s Medical College 56:955–960

    Google Scholar 

  • Schattner A, Merlin G, Hahn T (1981) Assay of an interferon induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet 397–499

    Google Scholar 

  • Schiller JH, Storer B, Witt PL (1990) Biological and clinical effects of the combination of β- and γ-interferons administered as a 5-day continuous infusion. Cancer Res 50:4588–4594

    PubMed  CAS  Google Scholar 

  • Shindo M, Okuno T, Matsumoto M (1988) Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic Hepatitis B. Hepatology 8:366–370

    Article  PubMed  CAS  Google Scholar 

  • Steis RG, Smith, JW, Urban WJ (1988) Resistance of recombinant interferon α 2a in hairy cell leucemia associated with neutralizing anti interferon antibodies. N Engl J Med 318:1409–1413

    Article  PubMed  CAS  Google Scholar 

  • Steward II WE (1981) Interferon inducers. In: The Interferon System. Springer Verlag, 27–57

    Google Scholar 

  • Sugino H, Mitani I, Koike M (1987) Detection of elevated levels of 2′–5′ A synthetase in serum from children with various infectious diseases. J Clin Microbiol 24:478–481

    Google Scholar 

  • Tamalgade JE, Tribble HR, Pennington RW (1987) Immunmodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47:2563–2570

    Google Scholar 

  • The IFNB Multiple Sclerosis Study Group (1993) Interferon beta 1b is effective in Relapsing-remitting Multiple Sclerosis. I. Clinical Results of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Neurology 43:655–661

    Google Scholar 

  • Treuner J, Dannecker G, Joester KE (1981) Pharmacological aspects of clinical stage I/II trials with human interferon beta in children. J Interferon Res 1:373–380

    Article  PubMed  CAS  Google Scholar 

  • Williams BRG, Read SE (1981) Detection of elevated levels of the interferon-induced enzyme, 2′–5′ A synthetase in infectious diseases and on parturition. In: De Maeyer E, Galasso G, Schellekens H (eds) The biology of the interferon system. Elsevier, Amsterdam, pp 111–114

    Google Scholar 

  • Wussow P von, Freund M, Block B (1987).Clinical sigificance of anti-IFN-alpha antibody titers during interferon therapy. Lancet: 635–636

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adolf-Gröber-Straße 12, Laupheim, 88471, Deutschland

    Dr. rer. nat Hans-Joachim Obert

Authors
  1. Dr. rer. nat Hans-Joachim Obert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Obert, HJ. (1995). Klinische Pharmakologie. In: Beta-Interferon. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97641-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-97641-4_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-59231-0

  • Online ISBN: 978-3-642-97641-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation